Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5410-5417

  Modi, Shanu ^a   Stopeck, Alison T ^a   Gordon, Michael S ^a   Mendelson, David ^a   Solit, David B ^a   Bagatell, Rochelle ^a   Ma, Weining ^a   Wheler, Jennifer ^a   Rosen, Neal ^a   Norton, Larry ^a   Cropp, Gillian F ^a   Johnson, Robert G ^a   Hannah, Alison L ^a   Hudis, Clifford A ^a  

^a KOSAN BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KOS 1297; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IN VIVO STUDY; INJECTION SITE REACTION; LIVER FUNCTION TEST; LOADING DRUG DOSE; LYMPHOCYTE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INDUCTION; PRURITUS; QT PROLONGATION; RASH; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR REGRESSION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 36849055007     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.7960     Document Type: Article

References (23)

1. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93:14536-14541, 1996
2. Solit DB, Rosen N: Hsp90: A novel target for cancer therapy. Curr Top Med Chem 6:1205-1214, 2006
3. Maloney A, Workman P: Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2:3-24, 2002
4. Whitesell L, Mimnaugh EG, De Cost B, et al: Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328, 1994
5. Basso A, Solit DB, Munster PN, et al: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER-2. Oncogene 21:1159-1166, 2002
6. Solit DB, Zheng FF, Drobnjak M, et al: 17-allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993, 2002
7. Solit DB, Basso AD, Olshen AB, et al: Inhibition of heat shock protein 90 function downregulates akt kinase and sensitizes tumors to taxol. Cancer Res 63:2139-2144, 2003
8. Banerji U, Walton M, Raynaud F, et al: Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11:7023-7032, 2005
9. Burger AM, Fiebig HH, Stinson SF, et al: 17-(allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15: 377-387, 2004
10. Nowakowski GS, McCollum AK, Ames MM, et al: A phase I trial of twice-weekly 17-allylaminodemethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087-6093, 2006
11. Banerji U, O'Donnell A, Scurr M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161, 2005
12. Ramanathan RK, Trump DL, Eiseman JL, et al: Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385-3391, 2005
13. Grem JL, Morrison G, Guo XD, et al: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893, 2005
14. Solit DB, Ivy P, Kopil C, et al: Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13: 1775-1782, 2007
15. Goetz MP, Toft D, Reid J, et al: Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087, 2005
16. Investigators Brochure: Tanespimycin, January 2007
17. Solit DB, Basso A, Smith-Jones P, et al: Inhibitors of Hsp90 induce the degradation of HER-2 and inhibit the growth of HER-2-dependent breast tumors. Presented at the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX
18. Leyland-Jones B: Dose scheduling: Herceptin. Oncology 61:31-36, 2001 (suppl)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
20. Cobleigh M, Frame D: Is trastuzumab every three weeks ready for prime time? J Clin Oncol, 21:3900-3901, 2003
21. Dang CT, Dannenberg AJ, Subbaramaiah K, et al: Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062-4067, 2004
22. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
23. Chiosis G, Neckers L: Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive. ACS Chem Biol 1:279-284, 2006